Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.41 |
| ▸ | MME | P08473 | 3/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | CPA1 | P15085 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101153 | 0.87 | ITGA4 (0.43) | LMNATDP1ITGB1ITGA4MME | |
| SCHEMBL7101158 | 0.87 | ITGA4 (0.43) | LMNATDP1ITGB1ITGA4MME | |
| SCHEMBL7097645 | 0.84 | MME (0.49) | NPSR1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL7101955 | 0.83 | PPARG (0.54) | NPSR1MEN1KMT2AMMEACE2 | |
| SCHEMBL7100747 | 0.83 | ITGA4 (0.51) | NPSR1LMNATDP1MEN1KMT2A | |
| SCHEMBL7100744 | 0.83 | ITGA4 (0.51) | NPSR1LMNATDP1MEN1KMT2A | |
| SCHEMBL7101959 | 0.83 | PPARG (0.54) | NPSR1MEN1KMT2AMMEACE2 | |
| SCHEMBL7102583 | 0.82 | NPSR1 (0.53) | NPSR1LMNATDP1MEN1KMT2A | |
| SCHEMBL7102575 | 0.82 | NPSR1 (0.53) | NPSR1LMNATDP1MEN1KMT2A | |
| SCHEMBL7099118 | 0.82 | ITGB1 (0.48) | NPSR1LMNATDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | NPSR1 1330/4885LMNA 2264/4885TDP1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.